InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Gosebruch Henry O, Director. Officer active across 4 companies, notably AbbVie Inc.. Cumulatively, 12 filings have been recorded. Breakdown: 2 buys · 2 sells. Total volume traded: €5.1m. Activity tracked since 7 September 2021. The latest transaction was filed on 19 August 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Gosebruch Henry O
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
6,662 shares0Common StockSEC:0001659625-26-000011:0
50,000 sharesCommon StockSEC:0001962918-25-000058:0
80,000 shares0Common StockSEC:0001610717-24-000065:0
15,000 shares@ US$12.6247100.0% of flowCommon StockSEC:0001610717-23-000290:0
Canonical exit: 18 Dec 2023 (T+90)
50,000 shares@ US$18.00100.0% of flowCommon StockSEC:0001209191-23-028878:0
Canonical exit: 7 Aug 2023 (T+90)
83,960 shares@ US$54.860.0012% mcap26.0% of flowCommon Stock, $0.01 par valueSEC:0001179110-22-003108:0
15,733 shares@ US$146.81050.0006% mcap12.1% of flowCommon Stock, $0.01 par valueSEC:0001179110-22-003107:0
83,960 shares@ US$54.8642.0% of flowCommon Stock, $0.01 par valueSEC:0001179110-22-003076:0
15,733 shares@ US$146.810519.6% of flowCommon Stock, $0.01 par valueSEC:0001179110-22-001923:0
30,156 shares@ US$149.5438.4% of flowCommon Stock, $0.01 par valueSEC:0001179110-22-001841:0
36,673 shares0Common Stock, $0.01 par valueSEC:0001179110-22-001513:0
30,000 shares0Common Stock, $0.01 par valueSEC:0001179110-21-008720:0
12 of 12 declarations
About Gosebruch Henry O
Henry O Gosebruch is a director. He has 11 filings in total. In the sampled recent filings, between 2021-09-10 and 2025-05-23, buys amount to EUR 998097 and sells to EUR 4118735. The companies mentioned are AbbVie Inc., where he is EVP, Chief Strategy Officer, ACELYRIN, Inc., where he is Director, and Neumora Therapeutics, Inc., where he is President & CEO.
